Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA's New Development Science Office Modeled On Modeling Office

Jan 13 2019

• By Derrick Gingery

LabmicroscopeDNAgel_1200x675

Related Content

Gene Therapies: Accelerated Approval Open For Some, But Not All, Neurodegenerative Disease Treatments

Jan 08 2019

J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven And Lilly

Jan 09 2019

J.P. Morgan Notebook Day 1: Pfizer, Gilead, Alnylam, Novartis, Sarepta, Deal Trends And Cell Therapy Challenges

Jan 08 2019

J.P. Morgan Notebook Day 4: US Generics Steady, UroGen, REGENXBIO, Dr. Reddy's In China, And Investor Sentiment Shifts

Jan 10 2019

Orange Book Policing May Increase, US FDA's Gottlieb Says

Jan 10 2019

J.P. Morgan Notebook Day 3: Biotech Feeling Government Shutdown, AstraZeneca, Denali, Allergan, Aptinyx, Sangamo

Jan 10 2019

Gene Therapy Oversight To Be Streamlined By US FDA, NIH

Aug 02 2018

Gene Therapy 'Cassettes' Could Speed, Cheapen Manufacturing, Gottlieb Says

May 24 2018

Office Of New Drugs Reorg Is Bigger Than Expected: US FDA Adds 11 Review Divisions

Jun 04 2018

Four Rules For Being A Consistent US FDA Reviewer From Peter Stein

Dec 10 2018

Drug Development Tool Qualification: US FDA Offers Three-Step Review Process

Dec 17 2018

Gottlieb Takes Aim At CROs’ ‘Outdated Processes’ In Push For Clinical Trial Digitization

Nov 26 2018

What’s The Plan? US FDA Drug Development Tool Qualification Process Requires “Cultural Change”

Dec 21 2018

Gene Therapy Guidance From US FDA Likely Needs Updating Sooner Rather Than Later

Nov 19 2018

Additional Topics

United States FDA Regulation BioPharmaceutical

More from US FDA

More from Agency Leadership

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window